RT Journal Article
SR Electronic
T1 A survey of patient and public perceptions and awareness of SARS-CoV-2-related risks among participants in India and South Africa
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.26.22279242
DO 10.1101/2022.08.26.22279242
A1 Mbamalu, Oluchi
A1 Surendran, Surya
A1 Nampoothiri, Vrinda
A1 Bonaconsa, Candice
A1 Edathadathil, Fabia
A1 Zhu, Nina
A1 Carter, Vanessa
A1 Lambert, Helen
A1 Tarrant, Carolyn
A1 Ahmad, Raheelah
A1 Brink, Adrian
A1 Steenkamp, Ebrahim
A1 Holmes, Alison
A1 Singh, Sanjeev
A1 Charani, Esmita
A1 Mendelson, Marc
YR 2022
UL http://medrxiv.org/content/early/2022/08/26/2022.08.26.22279242.abstract
AB A cross-sectional survey was performed among the adult population of participating countries, India and South Africa. The purpose of this study was to explore perceptions and awareness of SARS-CoV-2-related risks in the relevant countries. The main outcome measures were the proportion of participants aware of SARS-CoV-2, and their perception of infection risks.Self-administered questionnaires were used to collect data via a web- and paper-based survey over three months. For data capturing, Microsoft Excel was employed, and descriptive statistics used for presenting data. Pearson’s Chi-squared test was used to assess relationships between variables, and a p-value less than 0.05 was considered significant.There were 844 respondents (India: n=660, South Africa: n=184; response rate 87.6%), with a 61.1% vs 38.3% female to male ratio. Post-high-school or university education was the lowest qualification reported by most respondents in India (77.3%) and South Africa (79.3%). Sources of information about the pandemic were usually media and journal publications (73.2%), social media (64.6%), family and friends (47.7%) and government websites (46.2%). Most respondents correctly identified infection prevention measures (such as physical distancing, mask use), with 90.0% reporting improved hand hygiene practices since the pandemic. Hesitancy or refusal to accept the SARS-CoV-2 vaccine was reported among 17.9% and 50.9% of respondents in India and South Africa, respectively. Reasons cited included rushed vaccine development and the futility of vaccines for what respondents considered a self-limiting flu-like illness.Respondents identified public health promotion measures for SARS-CoV-2. Reported hesitancy to the up-take of SARS-CoV-2 vaccines was much higher in South Africa. Vaccination campaigns should consider robust public engagement and contextually fit communication strategies with multimodal, participatory online and offline initiatives to address public concerns, specifically towards vaccines developed for this pandemic and general vaccine hesitancy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Economic and Social Research Council (ESRC) as part of the Antimicrobial Cross Council Initiative supported by the seven UK research councils, the Global Challenges Research Fund (GCRF) as part of the ASPIRES project (https://www.imperial.ac.uk/arc/aspires/), the National Institute for Health Research, UK Department of Health [HPRU-2012-10047] in partnership with Public Health England and the National Research Foundation of South Africa (Grant Number: 129755). The funders did not have any role in the study design and conduct, review or approval of the manuscript, or the decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the relevant human research ethics committees at the Amrita Institute of Health Sciences, Kerala, India (Ref: IRB-AIMS-2020-232) and the University of Cape Town, South Africa (Ref: 311/2020).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available on a secure online portal, and can be accessed on request or included as supplementary information, if preferred.